$PPBT

Purple Biotech (NASDAQ:PPBT) shares rose 22.89% premarket Wednesday after the U.S. Patent Office granted a Notice of Allowance for its tri-specific antibody constructs. The patent expands the company's IP for its CAPTN-3 platform, which aims to accelerate cancer treatment development. Preclinical data for lead candidate IM1240 showed anti-tumor activity, with human trials planned for 2027.

Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2026 results and new preclinical data on its IM1240 tri-specific antibody. The company said IM1240 showed an 8-fold longer half-life and 16-fold higher exposure versus a non-capped variant, with reduced cytokines in toxicology work. Cash was $6.1 million at June 30, 2026, funding a runway to mid-2027. IM1240 is planned for clinical entry in 2027.

PURPLE BIOTECH LTD. (PPBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Purple Biotech Reports Second Quarter 2026 Financial Results New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240’s anti-tumor activity, favorable safety a

Purple Biotech presented preclinical EACR 2026 data on its CAPTN-3 program, IM1240. A non-GLP NHP toxicology study validated the CAPTN-3 masking strategy, reporting ~8-fold longer half-life and 16-fold higher exposure versus the non-capped variant IM1222, with markedly lower cytokine release. In patient-derived PD-1/chemo-resistant tumor samples, IM1240 showed anti-tumor activity requiring CD3 and NKG2A, and in NSCLC explants induced mature tertiary lymphoid structures. The company plans first-i

Purple Biotech (NASDAQ: PPBT) has established a Scientific Advisory Board (SAB) for its CAPTN-3 tri-specific antibody platform to guide its progression toward clinical-stage immunotherapy. The SAB includes experts in NK and T-cell biology and those with direct experience in developing approved T-cell engager therapies. This board will provide strategic guidance on translational science, NK and T cell biology, and clinical strategy as the company prepares for first-in-human studies.

Purple Biotech's CFO, Shai S. Lankry, has updated his equity holdings, revealing significant stock options and restricted stock units (RSUs). The filing shows options to purchase a total of 6,550,000 ordinary shares under the company's 2016 Equity-Based Incentive Plan, with varying exercise prices and expiration dates in 2030. Additionally, Lankry holds 3,254,167 unvested RSUs, which will be settled in ordinary shares based on time-based vesting conditions.

Michael Schickler, Head of Clinical & Reg Affairs at Purple Biotech (PPBT), has filed an initial ownership report detailing his holdings. The report indicates beneficial ownership of 9,254,472 Ordinary Shares, which include 6,958,334 unvested restricted stock units (RSUs). Schickler also holds several stock options with varying exercise prices and expiration dates, ranging from April 2027 to October 2030, some of which are fully vested while others vest in quarterly installments.

Purple Biotech announced a collaboration with Converge Bio to utilize generative AI for accelerating the development of its next-generation tri-specific antibody platform for oncology. This partnership aims to enhance the discovery, optimize developability, and expand capabilities against solid-tumor targets. The collaboration will integrate Converge Bio's AI-driven molecule design with Purple Biotech's CAPTN-3 conditional activation technology to generate optimized T cell engagers and high-quality candidates more rapidly.

Purple Biotech Ltd. announced that its CEO, Gil Efron, will step down from his role in August due to health considerations. Efron will transition to lead corporate development, and the company has begun a search for a new chief executive. Shares of Purple Biotech closed down 4.24% on the Nasdaq following the announcement.

This page from TradingView displays information related to the Return on Invested Capital (ROIC) percentage for Purple Biotech Ltd. Sponsored ADR, traded on the Munich Stock Exchange under the symbol 1YI0. The content indicates that the market is currently closed and provides navigation to financial data, but the article itself doesn't contain specific ROIC figures or analysis. It largely consists of website navigation and copyright information.